Lon Schneider, MD

Title(s)Professor of Psychiatry & the Behavioral Sciences
SchoolKeck School of Medicine of Usc
AddressCHP-216 1540 Alcazar Street
Health Sciences Campus
Los Angeles CA 90089-9009
Phone+1 323 442 7600
vCardDownload vCard
    Other Positions
    Title(s)Della Martin Chair in Psychiatry and Neuroscience


    Collapse Biography 
    Collapse Awards and Honors
    First Annual Dorothy Kirsten French Memorial LectureFirst Annual Dorothy Kirsten French Memorial Lecture
    Los Angeles/Brentwood VA Medical CenterTsai Memorial Lecture
    Los Angeles Alzheimer' Association11th and 21st Annual Research Awards
    American Association for Geriatric PsychiatrySenior Investigator Award
    Clinical Research, Alzheimer's AssociationSenator Mark Hatfield Award
    University of Pittsburgh School of Public HealthJay L. Foster Memorial Lecture
    Clinical Research, Alzheimer's AssociationSenator Mark Hatfield Award
    Los Angeles MagazineBest Doctors in Los Angeles
    Good HousekeepingThe 327 Best Mental Health Experts
    Woodward/White, Inc.1992  - 2009The Best Doctors in America

    Collapse Overview 
    Collapse Overview
    Lon S. Schneider, MD, MS, is professor of psychiatry, neurology, and gerontology at the Keck School of Medicine and Leonard Davis School of Gerontology of the University of Southern California; and holds the Della Martin Chair in Psychiatry and Neuroscience. He directs the USC California Alzheimer’s Disease Center (California Department of Health Services), the Geriatric Studies Center, and co-directs the clinical core of the USC NIA Alzheimer’s Disease Research Center. He holds a master’s degree in applied biometry and epidemiology. His work involves treatment development with novel metabolic and neuroregenerative compounds, outcomes assessment, and approaches to modelling, clinical trials methods and simulations, and, recently, in silico screening of medications for slowing Alzheimer’s disease. He is an associate editor or editorial board member of several publications, and serves on The Lancet Commission on dementia prevention, intervention, and care. He is a Fellow of the American College of Neuropsychopharmacology, and a Distinguished Life Fellow of the American Psychiatric Association.

    Collapse Research 
    Collapse Research Activities and Funding
    Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial
    NIH R01AG063826Aug 15, 2019 - Apr 30, 2025
    Role: Co-Principal Investigator
    (-)-Phenserine inhibition of neuronal death in Alzheimer?s disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial
    NIH R01AG062687May 1, 2019 - Feb 29, 2024
    Role: Principal Investigator
    Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials
    NIH R01AG051346Sep 1, 2018 - May 31, 2023
    Role: Co-Principal Investigator
    In Silico Screening of Medications for Slowing Alzheimer's Disease Progression.
    NIH R01AG057684Sep 15, 2017 - Mar 31, 2022
    Role: Co-Principal Investigator
    Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase I
    NIH UF1AG046148Sep 20, 2013 - Aug 31, 2017
    Role: Co-Principal Investigator
    Synthesis of Longer-Term Alzheimer Disease Studies in Order to Model and Improve
    NIH R01AG037561Apr 1, 2011 - Mar 31, 2016
    Role: Principal Investigator
    Estrogen Receptor-beta phytoSERMs for Management of Menopause and Memory Decline
    NIH R01AG033288Jun 1, 2010 - Nov 30, 2015
    Role: Principal Investigator
    Depression in Alzheimer's Disease Study 2 (DIADS-2)
    NIH U01MH066175Jun 10, 2003 - Feb 28, 2009
    Role: Principal Investigator
    CARBAMAZEPINE TRIAL IN AGITATED ALZHEIMERS OUTPATIENTS
    NIH R01MH048759Sep 30, 1992 - Aug 31, 1997
    Role: Principal Investigator
    GERIATRIC PSYCHIATRIC FELLOWSHIP PROGRAM
    NIH T01MH019213Sep 1, 1990 - Jun 30, 1993
    Role: Principal Investigator
    FACULTY SCHOLAR AWARD IN GERIATRIC MENTAL HEALTH
    NIH T01MH019074Sep 30, 1988 - Feb 28, 1993
    Role: Principal Investigator
    NIMH CLINICAL TRAINING
    NIH T01MH017392Jul 15, 1983 - Jun 30, 1990
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Featured Content 
    Collapse Twitter
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Preclinical assessment of a noncooled MR thermometry-based neurosurgical laser therapy system. J Neurosurg. 2024 Mar 08; 1-11. Singh H, Osswald CR, Rossman A, Knappe V, Schneider L, Floyd CL, Rolston JD. PMID: 38457800.
      View in: PubMed   Mentions:    Fields:    
    2. The Current Landscape of Prevention Trials in Dementia. Neurotherapeutics. 2022 Jan; 19(1):228-247. Lee J, Howard RS, Schneider LS. PMID: 38176792.
      View in: PubMed   Mentions: 1     Fields:    
    3. Comparison of relative change with effect size metrics in Alzheimer's disease clinical trials. J Neurol Neurosurg Psychiatry. 2023 Dec 14; 95(1):2-7. Goldberg TE, Lee S, Devanand DP, Schneider LS. PMID: 37979967.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    4. What the Gantenerumab Trials Teach Us about Alzheimer's Treatment. N Engl J Med. 2023 Nov 16; 389(20):1918-1920. Schneider LS. PMID: 37966291.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Association Between Self- and Proxy-Reported Depression and Quality of Life in Mild-Moderate Alzheimer's Disease. Am J Geriatr Psychiatry. 2024 01; 32(1):58-67. Joe E, Segal-Gidan F, Cummings JL, Galasko D, Tomaszewski Farias S, Johnson DK, Ross L, Yaffe K, Wang X, Schneider LS, Chui H, Ringman JM, California Alzheimer's Disease Center Investigators. PMID: 37827916; PMCID: PMC10843510.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Alzheimer's and Dementia Guidelines and Tables. Psychopharmacol Bull. 2023 07 12; 53(2):8-65. Schneider LS. PMID: 37489152; PMCID: PMC10363282.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies LRRC4C, LHX5-AS1 and nominates ancestry-specific loci PTPRK , GRB14 , and KIAA0825 as novel risk loci for Alzheimer's disease: the Alzheimer's Disease Genetics Consortium. medRxiv. 2023 Jul 08. Rajabli F, Benchek P, Tosto G, Kushch N, Sha J, Bazemore K, Zhu C, Lee WP, Haut J, Hamilton-Nelson KL, Wheeler NR, Zhao Y, Farrell JJ, Grunin MA, Leung YY, Kuksa PP, Li D, Lucio da Fonseca E, Mez JB, Palmer EL, Pillai J, Sherva RM, Song YE, Zhang X, Iqbal T, Pathak O, Valladares O, Kuzma AB, Abner E, Adams PM, Aguirre A, Albert MS, Albin RL, Allen M, Alvarez L, Apostolova LG, Arnold SE, Asthana S, Atwood CS, Ayres G, Baldwin CT, Barber RC, Barnes LL, Barral S, Beach TG, Becker JT, Beecham GW, Beekly D, Benitez BA, Bennett D, Bertelson J, Bird TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Brewer J, Burke JR, Burns JM, Buxbaum JD, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carlsson CM, Carney RM, Carrasquillo MM, Chasse S, Chesselet MF, Chin NA, Chui HC, Chung J, Craft S, Crane PK, Cribbs DH, Crocco EA, Cruchaga C, Cuccaro ML, Cullum M, Darby E, Davis B, De Jager PL, DeCarli C, DeToledo J, Dick M, Dickson DW, Dombroski BA, Doody RS, Duara R, Ertekin-Taner N, Evans DA, Faber KM, Fairchild TJ, Fallon KB, Fardo DW, Farlow MR, Fernandez-Hernandez V, Ferris S, Foroud TM, Frosch MP, Fulton-Howard B, Galasko DR, Gamboa A, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Goate AM, Grabowski TJ, Graff-Radford NR, Green RC, Growdon JH, Hakonarson H, Hall J, Hamilton RL, Harari O, Hardy J, Harrell LE, Head E, Henderson VW, Hernandez M, Hohman T, Honig LS, Huebinger RM, Huentelman MJ, Hulette CM, Hyman BT, Hynan LS, Ibanez L, Jarvik GP, Jayadev S, Jin LW, Johnson K, Johnson L, Kamboh MI, Karydas AM, Katz MJ, Kauwe JS, Kaye JA, Keene CD, Khaleeq A, Kim R, Knebl J, Kowall NW, Kramer JH, Kukull WA, LaFerla FM, Lah JJ, Larson EB, Lerner A, Leverenz JB, Levey AI, Lieberman AP, Lipton RB, Logue M, Lopez OL, Lunetta KL, Lyketsos CG, Mains D, Margaret FE, Marson DC, Martin ERR, Martiniuk F, Mash DC, Masliah E, Massman P, Masurkar A, McCormick WC, McCurry SM, McDavid AN, McDonough S, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Montine TJ, Monuki ES, Morris JC, Mukherjee S, Myers AJ, Nguyen T, O'Bryant S, Olichney JM, Ory M, Palmer R, Parisi JE, Paulson HL, Pavlik V, Paydarfar D, Perez V, Peskind E, Petersen RC, Pierce A, Polk M, Poon WW, Potter H, Qu L, Quiceno M, Quinn JF, Raj A, Raskind M, Reiman EM, Reisberg B, Reisch JS, Ringman JM, Roberson ED, Rodriguear M, Rogaeva E, Rosen HJ, Rosenberg RN, Royall DR, Sager MA, Sano M, Saykin AJ, Schneider JA, Schneider LS, Seeley WW, Slifer SH, Small S, Smith AG, Smith JP, Sonnen JA, Spina S, St George-Hyslop P, Stern RA, Stevens AB, Strittmatter SM, Sultzer D, Swerdlow RH, Tanzi RE, Tilson JL, Trojanowski JQ, Troncoso JC, Tsuang DW, Van Deerlin VM, van Eldik LJ, Vance JM, Vardarajan BN, Vassar R, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Whitehead PL, Wijsman EM, Wilhelmsen KC, Williams B, Williamson J, Wilms H, Wingo TS, Wisniewski T, Woltjer RL, Woon M, Wright CB, Wu CK, Younkin SG, Yu CE, Yu L, Zhu X, Kunkle BW, Bush WS, Wang LS, Farrer LA, Haines JL, et al. PMID: 37461624; PMCID: PMC10350126.
      View in: PubMed   Mentions:
    8. A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter. Transl Neurodegener. 2023 05 12; 12(1):24. LaBarbera KM, Sheline YI, Izzo NJ, Yuede CM, Waybright L, Yurko R, Edwards HM, Gardiner WD, Blennow K, Zetterberg H, Börjesson-Hanson A, Morgan R, Davis CS, Guttendorf RJ, Schneider LS, DeKosky S, LeVine H, Grundman M, Caggiano AO, Cirrito JR, Catalano SM, Hamby ME. PMID: 37173791; PMCID: PMC10176668.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    9. The relationship of history of psychiatric and substance use disorders on risk of dementia among racial and ethnic groups in the United States. Front Psychiatry. 2023; 14:1165262. Aranda MP, Liang J, Wang X, Schneider LS, Chui HC. PMID: 37168087; PMCID: PMC10165105.
      View in: PubMed   Mentions:
    10. Reliability of the NACC Telephone-administered Neuropsychological Battery (T-cog) and Montreal Cognitive Assessment for participants in the USC ADRC. Alzheimers Dement (Amst). 2023 Jan-Mar; 15(1):e12406. Howard RS, Goldberg TE, Luo J, Munoz C, Schneider LS. PMID: 36911358; PMCID: PMC9994164.
      View in: PubMed   Mentions:
    11. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry. 2023 Feb; 22(1):48-74. Correll CU, Solmi M, Cortese S, Fava M, Højlund M, Kraemer HC, McIntyre RS, Pine DS, Schneider LS, Kane JM. PMID: 36640403; PMCID: PMC9840514.
      View in: PubMed   Mentions: 13  
    12. Viewpoint: When It Comes to Lecanemab (and Donanemab), How Might We Think about 'Reasonable and Necessary'? J Prev Alzheimers Dis. 2023; 10(3):342-343. Schneider LS. PMID: 37357268.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. The Safety of Pimavanserin for Parkinson's Disease and Efforts to Reduce Antipsychotics for People With Dementia. Am J Psychiatry. 2022 08; 179(8):519-521. Schneider LS. PMID: 35921393.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    14. Nutrition state of science and dementia prevention: recommendations of the Nutrition for Dementia Prevention Working Group. Lancet Healthy Longev. 2022 07; 3(7):e501-e512. Yassine HN, Samieri C, Livingston G, Glass K, Wagner M, Tangney C, Plassman BL, Ikram MA, Voigt RM, Gu Y, O'Bryant S, Minihane AM, Craft S, Fink HA, Judd S, Andrieu S, Bowman GL, Richard E, Albensi B, Meyers E, Khosravian S, Solis M, Carrillo M, Snyder H, Grodstein F, Scarmeas N, Schneider LS. PMID: 35821792; PMCID: PMC9273104.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    15. The Current Landscape of Prevention Trials in Dementia. Neurotherapeutics. 2022 01; 19(1):228-247. Lee J, Howard RS, Schneider LS. PMID: 35587314; PMCID: PMC9130372.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    16. The small HDL particle hypothesis of Alzheimer's disease. Alzheimers Dement. 2023 02; 19(2):391-404. Martinez AE, Weissberger G, Kuklenyik Z, He X, Meuret C, Parekh T, Rees JC, Parks BA, Gardner MS, King SM, Collier TS, Harrington MG, Sweeney MD, Wang X, Zlokovic BV, Joe E, Nation DA, Schneider LS, Chui HC, Barr JR, Han SD, Krauss RM, Yassine HN. PMID: 35416404; PMCID: PMC10563117.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    17. The human anti-ganglioside GM1 autoantibody response following traumatic and surgical central nervous system insults. Neurosci Res. 2022 Aug; 181:105-114. Schneider L, Rezaeezade-Roukerd M, Faulkner J, Reichert E, Abou-Al-Shaar H, Flis A, Rubiano AM, Hawryluk GWJ. PMID: 35405180.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease. Alzheimers Dement (N Y). 2022; 8(1):e12286. Wang G, Liu L, Li Y, Aschenbrenner AJ, Bateman RJ, Delmar P, Schneider LS, Kennedy RE, Cutter GR, Xiong C. PMID: 35415211; PMCID: PMC8984094.
      View in: PubMed   Mentions: 2  
    19. Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomes. Alzheimers Dement (N Y). 2022; 8(1):e12258. Raikes AC, Hernandez GD, Matthews DC, Lukic AS, Law M, Shi Y, Schneider LS, Brinton RD. PMID: 35310526; PMCID: PMC8919249.
      View in: PubMed   Mentions: 6  
    20. Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race. Alzheimers Dement. 2022 04; 18(4):867-868. Babulal GM, Franzen S, Abner EL, Smith JE, van den Berg E, Mindt MR, van Bruchem-Visser RL, Schneider LS, Prins ND, Papma JM. PMID: 35142024; PMCID: PMC9907789.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    21. Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial. J Prev Alzheimers Dis. 2022; 9(4):625-634. Schneider LS, Bennett DA, Farlow MR, Peskind ER, Raskind MA, Sano M, Stern Y, Haneline S, Welsh-Bohmer KA, O'Neil J, Walter R, Maresca S, Culp M, Alexander R, Saunders AM, Burns DK, Chiang C. PMID: 36281666.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    22. High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations. J Alzheimers Dis. 2022; 90(1):333-348. Sturchio A, Dwivedi AK, Malm T, Wood MJA, Cilia R, Sharma JS, Hill EJ, Schneider LS, Graff-Radford NR, Mori H, Nübling G, El Andaloussi S, Svenningsson P, Ezzat K, Espay AJ, Dominantly Inherited Alzheimer Consortia (DIAN). PMID: 36120786; PMCID: PMC9661329.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    23. A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer's Disease. J Prev Alzheimers Dis. 2022; 9(2):247-254. Schneider LS, Laudon M, Nir T, Caceres J, Ianniciello G, Capulli M, Zisapel N. PMID: 35542997.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    24. Editorial: Aducanumab Trials EMERGE But Don't ENGAGE. J Prev Alzheimers Dis. 2022; 9(2):193-196. Schneider LS. PMID: 35542990.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    25. Impact of potential modifications to Alzheimer's disease clinical trials in response to disruption by COVID-19: a simulation study. Alzheimers Res Ther. 2021 12 20; 13(1):201. Schneider LS, Qiu Y, Thomas RG, Evans C, Jacobs DM, Jin S, Kaye JA, LaCroix AZ, Messer K, Salmon DP, Sano M, Schafer K, Feldman HH. PMID: 34930444; PMCID: PMC8686345.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsPHPublic Health
    26. Alzheimer's drugs: Does reducing amyloid work? Science. 2021 10 29; 374(6567):544-545. Thambisetty M, Howard R, Glymour MM, Schneider LS. PMID: 34709898.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    27. Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon-like peptide-1 receptor agonists. Alzheimers Dement. 2022 03; 18(3):478-497. Yassine HN, Solomon V, Thakral A, Sheikh-Bahaei N, Chui HC, Braskie MN, Schneider LS, Talbot K. PMID: 34647685; PMCID: PMC8940606.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    28. Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria. Alzheimers Dement. 2022 04; 18(4):810-823. Franzen S, Smith JE, van den Berg E, Rivera Mindt M, van Bruchem-Visser RL, Abner EL, Schneider LS, Prins ND, Babulal GM, Papma JM. PMID: 34590409; PMCID: PMC8964823.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    29. Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report. Alzheimers Dement. 2022 06; 18(6):1109-1118. Jicha GA, Abner EL, Arnold SE, Carrillo MC, Dodge HH, Edland SD, Fargo KN, Feldman HH, Goldstein LB, Hendrix J, Peters R, Robillard JM, Schneider LS, Titiner JR, Weber CJ, Clinical Trial Advancement & Methodology Professional Interest Area of the International Society to . PMID: 34590417; PMCID: PMC8960469.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    30. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 07; 20(7):537-547. Burns DK, Alexander RC, Welsh-Bohmer KA, Culp M, Chiang C, O'Neil J, Evans RM, Harrigan P, Plassman BL, Burke JR, Wu J, Lutz MW, Haneline S, Schwarz AJ, Schneider LS, Yaffe K, Saunders AM, Ratti E, TOMMORROW study investigators. PMID: 34146512.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    31. High cerebrospinal amyloid-β 42 is associated with normal cognition in individuals with brain amyloidosis. EClinicalMedicine. 2021 Aug; 38:100988. Sturchio A, Dwivedi AK, Young CB, Malm T, Marsili L, Sharma JS, Mahajan A, Hill EJ, Andaloussi SE, Poston KL, Manfredsson FP, Schneider LS, Ezzat K, Espay AJ. PMID: 34505023; PMCID: PMC8413261.
      View in: PubMed   Mentions: 35  
    32. The need to show minimum clinically important differences in Alzheimer's disease trials. Lancet Psychiatry. 2021 11; 8(11):1013-1016. Liu KY, Schneider LS, Howard R. PMID: 34087114.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    33. Development of novel measures for Alzheimer's disease prevention trials (NoMAD). Contemp Clin Trials. 2021 07; 106:106425. Bell SA, Cohen HR, Lee S, Kim H, Ciarleglio A, Andrews H, Rivera AM, Igwe K, Brickman AM, Devanand DP, Harvey PD, Schneider LS, Goldberg TE. PMID: 33933666; PMCID: PMC10001317.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    34. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol. 2021 06; 20(6):484-496. Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, Rowe CC, Salloway S, Schneider LS, Cummings JL, Feldman HH. PMID: 33933186; PMCID: PMC8339877.
      View in: PubMed   Mentions: 201     Fields:    Translation:Humans
    35. Value-Generating Exploratory Trials in Neurodegenerative Dementias. Neurology. 2021 05 18; 96(20):944-954. Friedman LG, McKeehan N, Hara Y, Cummings JL, Matthews DC, Zhu J, Mohs RC, Wang D, Hendrix SB, Quintana M, Schneider LS, Grundman M, Dickson SP, Feldman HH, Jaeger J, Finger EC, Ryan JM, Niehoff D, Dickinson SL, Markowitz JT, Owen M, Travaglia A, Fillit HM. PMID: 33674360; PMCID: PMC8205472.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    36. The efficacy of antidepressant medication and interpersonal psychotherapy for adult acute-phase depression: study protocol of a systematic review and meta-analysis of individual participant data. BJPsych Open. 2021 Feb 19; 7(2):e56. Driessen E, Cohen ZD, Weissman MM, Markowitz JC, Weitz ES, Hollon SD, Browne DT, Rucci P, Corda C, Menchetti M, Bagby RM, Quilty LC, O'Hara MW, Zlotnick C, Pearlstein T, Blom MBJ, Altamura M, Gois C, Schneider LS, Twisk JWR, Cuijpers P. PMID: 33602371; PMCID: PMC8058821.
      View in: PubMed   Mentions: 1  
    37. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Alzheimers Dement. 2021 08; 17(8):1365-1382. Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Waybright L, Look G, Rishton G, Safferstein H, Hamby ME, Williams C, Sadlek K, Edwards HM, Davis CS, Grundman M, Schneider LS, DeKosky ST, Chelsky D, Pike I, Henstridge C, Blennow K, Zetterberg H, LeVine H, Spires-Jones TL, Cirrito JR, Catalano SM. PMID: 33559354; PMCID: PMC8349378.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    38. Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults. Brain Behav Immun. 2021 05; 94:299-307. Albrecht DS, Sagare A, Pachicano M, Sweeney MD, Toga A, Zlokovic B, Chui H, Joe E, Schneider L, Morris JC, Benzinger T, Pa J. PMID: 33486003; PMCID: PMC8793040.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    39. Soluble Amyloid-β Consumption in Alzheimer's Disease. J Alzheimers Dis. 2021; 82(4):1403-1415. Espay AJ, Sturchio A, Schneider LS, Ezzat K. PMID: 34151810.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    40. Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial. Alzheimers Dement (N Y). 2020; 6(1):e12107. Hernandez GD, Solinsky CM, Mack WJ, Kono N, Rodgers KE, Wu CY, Mollo AR, Lopez CM, Pawluczyk S, Bauer G, Matthews D, Shi Y, Law M, Rogawski MA, Schneider LS, Brinton RD. PMID: 33344752; PMCID: PMC7744018.
      View in: PubMed   Mentions: 10  
    41. Associations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid. J Neurosci. 2020 10 28; 40(44):8573-8586. Albrecht D, Isenberg AL, Stradford J, Monreal T, Sagare A, Pachicano M, Sweeney M, Toga A, Zlokovic B, Chui H, Joe E, Schneider L, Conti P, Jann K, Pa J. PMID: 33046556; PMCID: PMC7605425.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    42. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020 08 08; 396(10248):413-446. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, Costafreda SG, Dias A, Fox N, Gitlin LN, Howard R, Kales HC, Kivimäki M, Larson EB, Ogunniyi A, Orgeta V, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N. PMID: 32738937; PMCID: PMC7392084.
      View in: PubMed   Mentions: 2392     Fields:    Translation:HumansPHPublic Health
    43. Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial. EBioMedicine. 2020 Sep; 59:102883. Arellanes IC, Choe N, Solomon V, He X, Kavin B, Martinez AE, Kono N, Buennagel DP, Hazra N, Kim G, D'Orazio LM, McCleary C, Sagare A, Zlokovic BV, Hodis HN, Mack WJ, Chui HC, Harrington MG, Braskie MN, Schneider LS, Yassine HN. PMID: 32690472; PMCID: PMC7502665.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    44. Composite cognitive and functional measures for early stage Alzheimer's disease trials. Alzheimers Dement (Amst). 2020; 12(1):e12017. Schneider LS, Goldberg TE. PMID: 32432155; PMCID: PMC7233425.
      View in: PubMed   Mentions: 32  
    45. Response to peer commentaries: Composite cognitive and functional measures for early stage Alzheimer's disease trials. Alzheimers Dement (Amst). 2020; 12(1):e12024. Schneider LS, Goldberg TE. PMID: 32432156; PMCID: PMC7233419.
      View in: PubMed   Mentions:
    46. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020 05; 581(7806):71-76. Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, Pachicano M, Joe E, Nelson AR, D'Orazio LM, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, Schneider LS, Morris JC, Reiman EM, Caselli RJ, Chui HC, Tcw J, Chen Y, Pa J, Conti PS, Law M, Toga AW, Zlokovic BV. PMID: 32376954; PMCID: PMC7250000.
      View in: PubMed   Mentions: 439     Fields:    Translation:HumansCells
    47. A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid. Alzheimers Dement. 2020 06; 16(6):821-830. Sweeney MD, Sagare AP, Pachicano M, Harrington MG, Joe E, Chui HC, Schneider LS, Montagne A, Ringman JM, Fagan AM, Morris JC, Pa J, Nation DA, Toga AW, Zlokovic BV. PMID: 32301266; PMCID: PMC7986963.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    48. The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. Alzheimers Res Ther. 2020 03 02; 12(1):21. Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM, Synaptic Health Endpoints Working Group. PMID: 32122400; PMCID: PMC7053087.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCells
    49. Using practice effects for targeted trials or sub-group analysis in Alzheimer's disease: How practice effects predict change over time. PLoS One. 2020; 15(2):e0228064. Wang G, Kennedy RE, Goldberg TE, Fowler ME, Cutter GR, Schneider LS. PMID: 32084191; PMCID: PMC7034859.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    50. Pragmatic Trials and Repurposed Drugs for Alzheimer Disease. JAMA Neurol. 2020 02 01; 77(2):162-163. Schneider LS. PMID: 31738375.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    51. Commentary: The EU/US Task Force's Future for Anti-Amyloid Trials: Faites Vos Jeux. J Prev Alzheimers Dis. 2020; 7(3):199-200. Schneider LS. PMID: 32463075.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. Progression of Alzheimer's Disease by Self-Reported Cancer History in the Alzheimer's Disease Neuroimaging Initiative. J Alzheimers Dis. 2020; 76(2):691-701. Fowler ME, Triebel KL, Cutter GR, Schneider LS, Kennedy RE, Alzheimer’s Disease Neuroimaging Initiative. PMID: 32538844; PMCID: PMC7928167.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    53. Retrospective analysis of phytoSERM for management of menopause-associated vasomotor symptoms and cognitive decline: a pilot study on pharmacogenomic effects of mitochondrial haplogroup and APOE genotype on therapeutic efficacy. Menopause. 2020 01; 27(1):57-65. Wang Y, Hernandez G, Mack WJ, Schneider LS, Yin F, Brinton RD. PMID: 31567873; PMCID: PMC7100617.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    54. Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2019 Nov 01; 76(11):1330-1339. Schneider LS, Thomas RG, Hendrix S, Rissman RA, Brewer JB, Salmon DP, Oltersdorf T, Okuda T, Feldman HH, Alzheimer’s Disease Cooperative Study TCAD Study Group. PMID: 31282954; PMCID: PMC6618817.
      View in: PubMed   Mentions: 10     Fields:    
    55. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimers Dement. 2019 11; 15(11):1427-1436. Ehrhardt S, Porsteinsson AP, Munro CA, Rosenberg PB, Pollock BG, Devanand DP, Mintzer J, Rajji TK, Ismail Z, Schneider LS, Baksh SN, Drye LT, Avramopoulos D, Shade DM, Lyketsos CG, S-CitAD Research Group. PMID: 31587995; PMCID: PMC6889953.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    56. Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. Neurology. 2019 10 08; 93(15):e1474-e1484. Schneider LS, Geffen Y, Rabinowitz J, Thomas RG, Schmidt R, Ropele S, Weinstock M, Ladostigil Study Group. PMID: 31492718; PMCID: PMC7010322.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCTClinical Trials
    57. The risks and uses of dietary supplements. Lancet Neurol. 2019 09; 18(9):814. Schneider LS. PMID: 31397284.
      View in: PubMed   Mentions:    Fields:    
    58. Safety and feasibility of estrogen receptor-β targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial. Menopause. 2019 08; 26(8):874-884. Schneider LS, Hernandez G, Zhao L, Franke AA, Chen YL, Pawluczyk S, Mack WJ, Brinton RD. PMID: 30889096; PMCID: PMC6663614.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    59. Treatment Options for Agitation in Dementia. Curr Treat Options Neurol. 2019 Jun 24; 21(7):30. Ringman JM, Schneider L. PMID: 31231784.
      View in: PubMed   Mentions: 9  
    60. A randomized clinical trial to evaluate home-based assessment of people over 75 years old. Alzheimers Dement. 2019 05; 15(5):615-624. Sano M, Zhu CW, Kaye J, Mundt JC, Hayes TL, Ferris S, Thomas RG, Sun CK, Jiang Y, Donohue MC, Schneider LS, Egelko S, Aisen PS, Feldman HH, Alzheimer Disease Cooperative Study Investigators. PMID: 30872114.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. Alzheimers Dement (N Y). 2019; 5:20-26. Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, Guttendorf R, Higgin M, Pribyl J, Mozzoni K, Safferstein H, Catalano SM. PMID: 30723776; PMCID: PMC6352291.
      View in: PubMed   Mentions: 42  
    62. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019 02; 25(2):270-276. Nation DA, Sweeney MD, Montagne A, Sagare AP, D'Orazio LM, Pachicano M, Sepehrband F, Nelson AR, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, Schneider LS, Morris JC, Chui HC, Law M, Toga AW, Zlokovic BV. PMID: 30643288; PMCID: PMC6367058.
      View in: PubMed   Mentions: 613     Fields:    Translation:Humans
    63. Evaluation of Medicare Claims Data as a Tool to Identify Dementia. J Alzheimers Dis. 2019; 67(2):769-778. Lee E, Gatz M, Tseng C, Schneider LS, Pawluczyk S, Wu AH, Deapen D. PMID: 30689589; PMCID: PMC7164318.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    64. Vascular dysfunction-The disregarded partner of Alzheimer's disease. Alzheimers Dement. 2019 01; 15(1):158-167. Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, Harrington MG, Pa J, Law M, Wang DJJ, Jacobs RE, Doubal FN, Ramirez J, Black SE, Nedergaard M, Benveniste H, Dichgans M, Iadecola C, Love S, Bath PM, Markus HS, Al-Shahi Salman R, Allan SM, Quinn TJ, Kalaria RN, Werring DJ, Carare RO, Touyz RM, Williams SCR, Moskowitz MA, Katusic ZS, Lutz SE, Lazarov O, Minshall RD, Rehman J, Davis TP, Wellington CL, González HM, Yuan C, Lockhart SN, Hughes TM, Chen CLH, Sachdev P, O'Brien JT, Skoog I, Pantoni L, Gustafson DR, Biessels GJ, Wallin A, Smith EE, Mok V, Wong A, Passmore P, Barkof F, Muller M, Breteler MMB, Román GC, Hamel E, Seshadri S, Gottesman RF, van Buchem MA, Arvanitakis Z, Schneider JA, Drewes LR, Hachinski V, Finch CE, Toga AW, Wardlaw JM, Zlokovic BV. PMID: 30642436; PMCID: PMC6338083.
      View in: PubMed   Mentions: 278     Fields:    Translation:Humans
    65. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimers Dement. 2019 02; 15(2):292-312. Babulal GM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, Bahar-Fuchs A, Bell J, Bowman GL, Brickman AM, Chételat G, Ciro C, Cohen AD, Dilworth-Anderson P, Dodge HH, Dreux S, Edland S, Esbensen A, Evered L, Ewers M, Fargo KN, Fortea J, Gonzalez H, Gustafson DR, Head E, Hendrix JA, Hofer SM, Johnson LA, Jutten R, Kilborn K, Lanctôt KL, Manly JJ, Martins RN, Mielke MM, Morris MC, Murray ME, Oh ES, Parra MA, Rissman RA, Roe CM, Santos OA, Scarmeas N, Schneider LS, Schupf N, Sikkes S, Snyder HM, Sohrabi HR, Stern Y, Strydom A, Tang Y, Terrera GM, Teunissen C, Melo van Lent D, Weinborn M, Wesselman L, Wilcock DM, Zetterberg H, O'Bryant SE, International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association. PMID: 30555031; PMCID: PMC6368893.
      View in: PubMed   Mentions: 212     Fields:    Translation:Humans
    66. Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis. JAMA Netw Open. 2018 11 02; 1(7):e184080. Kennedy RE, Cutter GR, Fowler ME, Schneider LS. PMID: 30646339; PMCID: PMC6324361.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    67. Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2018 11; 33(7):450-457. Tao Y, Peters ME, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Munro CA. PMID: 29969907; PMCID: PMC6219457.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    68. Analysis of shared heritability in common disorders of the brain. Science. 2018 06 22; 360(6395). Brainstorm Consortium, Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, Escott-Price V, Falcone GJ, Gormley P, Malik R, Patsopoulos NA, Ripke S, Wei Z, Yu D, Lee PH, Turley P, Grenier-Boley B, Chouraki V, Kamatani Y, Berr C, Letenneur L, Hannequin D, Amouyel P, Boland A, Deleuze JF, Duron E, Vardarajan BN, Reitz C, Goate AM, Huentelman MJ, Kamboh MI, Larson EB, Rogaeva E, St George-Hyslop P, Hakonarson H, Kukull WA, Farrer LA, Barnes LL, Beach TG, Demirci FY, Head E, Hulette CM, Jicha GA, Kauwe JSK, Kaye JA, Leverenz JB, Levey AI, Lieberman AP, Pankratz VS, Poon WW, Quinn JF, Saykin AJ, Schneider LS, Smith AG, Sonnen JA, Stern RA, Van Deerlin VM, Van Eldik LJ, Harold D, Russo G, Rubinsztein DC, Bayer A, Tsolaki M, Proitsi P, Fox NC, Hampel H, Owen MJ, Mead S, Passmore P, Morgan K, Nöthen MM, Rossor M, Lupton MK, Hoffmann P, Kornhuber J, Lawlor B, McQuillin A, Al-Chalabi A, Bis JC, Ruiz A, Boada M, Seshadri S, Beiser A, Rice K, van der Lee SJ, De Jager PL, Geschwind DH, Riemenschneider M, Riedel-Heller S, Rotter JI, Ransmayr G, Hyman BT, Cruchaga C, Alegret M, Winsvold B, Palta P, Farh KH, Cuenca-Leon E, Furlotte N, Kurth T, Ligthart L, Terwindt GM, Freilinger T, Ran C, Gordon SD, Borck G, Adams HHH, Lehtimäki T, Wedenoja J, Buring JE, Schürks M, Hrafnsdottir M, Hottenga JJ, Penninx B, Artto V, Kaunisto M, Vepsäläinen S, Martin NG, Montgomery GW, Kurki MI, Hämäläinen E, Huang H, Huang J, Sandor C, Webber C, Muller-Myhsok B, Schreiber S, Salomaa V, Loehrer E, Göbel H, Macaya A, Pozo-Rosich P, Hansen T, Werge T, Kaprio J, Metspalu A, Kubisch C, Ferrari MD, Belin AC, van den Maagdenberg AMJM, Zwart JA, Boomsma D, Eriksson N, Olesen J, Chasman DI, Nyholt DR, Avbersek A, Baum L, Berkovic S, Bradfield J, Buono RJ, Catarino CB, Cossette P, De Jonghe P, Depondt C, Dlugos D, Ferraro TN, French J, Hjalgrim H, Jamnadas-Khoda J, Kälviäinen R, Kunz WS, Lerche H, Leu C, Lindhout D, Lo W, Lowenstein D, McCormack M, Møller RS, Molloy A, Ng PW, Oliver K, Privitera M, Radtke R, Ruppert AK, Sander T, Schachter S, Schankin C, Scheffer I, Schoch S, Sisodiya SM, Smith P, Sperling M, Striano P, Surges R, Thomas GN, Visscher F, Whelan CD, Zara F, Heinzen EL, Marson A, Becker F, Stroink H, Zimprich F, Gasser T, Gibbs R, Heutink P, Martinez M, Morris HR, Sharma M, Ryten M, Mok KY, Pulit S, Bevan S, Holliday E, Attia J, Battey T, Boncoraglio G, Thijs V, Chen WM, Mitchell B, Rothwell P, Sharma P, Sudlow C, Vicente A, Markus H, Kourkoulis C, Pera J, Raffeld M, Silliman S, Boraska Perica V, Thornton LM, Huckins LM, William Rayner N, Lewis CM, Gratacos M, Rybakowski F, Keski-Rahkonen A, Raevuori A, Hudson JI, Reichborn-Kjennerud T, Monteleone P, Karwautz A, Mannik K, Baker JH, O'Toole JK, Trace SE, Davis OSP, Helder SG, Ehrlich S, Herpertz-Dahlmann B, Danner UN, van Elburg AA, Clementi M, Forzan M, Docampo E, Lissowska J, Hauser J, Tortorella A, Maj M, Gonidakis F, Tziouvas K, Papezova H, Yilmaz Z, Wagner G, Cohen-Woods S, Herms S, Julià A, Rabionet R, Dick DM, Ripatti S, Andreassen OA, Espeseth T, Lundervold AJ, Steen VM, Pinto D, Scherer SW, Aschauer H, Schosser A, Alfredsson L, Padyukov L, Halmi KA, Mitchell J, Strober M, Bergen AW, Kaye W, Szatkiewicz JP, Cormand B, Ramos-Quiroga JA, Sánchez-Mora C, Ribasés M, Casas M, Hervas A, Arranz MJ, Haavik J, Zayats T, Johansson S, Williams N, Dempfle A, Rothenberger A, Kuntsi J, Oades RD, Banaschewski T, Franke B, Buitelaar JK, Arias Vasquez A, Doyle AE, Reif A, Lesch KP, Freitag C, Rivero O, Palmason H, Romanos M, Langley K, Rietschel M, Witt SH, Dalsgaard S, Børglum AD, Waldman I, Wilmot B, Molly N, Bau CHD, Crosbie J, Schachar R, et al. PMID: 29930110; PMCID: PMC6097237.
      View in: PubMed   Mentions: 685     Fields:    Translation:Humans
    69. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. Alzheimers Dement (N Y). 2018; 4:150-160. Tariot PN, Lopera F, Langbaum JB, Thomas RG, Hendrix S, Schneider LS, Rios-Romenets S, Giraldo M, Acosta N, Tobon C, Ramos C, Espinosa A, Cho W, Ward M, Clayton D, Friesenhahn M, Mackey H, Honigberg L, Sanabria Bohorquez S, Chen K, Walsh T, Langlois C, Reiman EM, Alzheimer's Prevention Initiative. PMID: 29955659; PMCID: PMC6021543.
      View in: PubMed   Mentions: 72  
    70. Pimavanserin for patients with Alzheimer's disease psychosis. Lancet Neurol. 2018 03; 17(3):194-195. Schneider LS. PMID: 29452674.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    71. Precision pharmacology for Alzheimer's disease. Pharmacol Res. 2018 04; 130:331-365. Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S, Alzheimer Precision Medicine Initiative (APMI). PMID: 29458203; PMCID: PMC8505114.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimals
    72. Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor β-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women. Menopause. 2018 02; 25(2):191-196. Hernandez G, Zhao L, Franke AA, Chen YL, Mack WJ, Brinton RD, Schneider LS. PMID: 28926513; PMCID: PMC5771891.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    73. Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions. Alzheimers Res Ther. 2018 01 15; 10(1):4. Geifman N, Kennedy RE, Schneider LS, Buchan I, Brinton RD. PMID: 29370871; PMCID: PMC6389228.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    74. (-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease. Curr Alzheimer Res. 2018; 15(9):883-891. Becker RE, Greig NH, Lahiri DK, Bledsoe J, Majercik S, Ballard C, Aarsland D, Schneider LS, Flanagan D, Govindarajan R, Sano M, Ferrucci L, Kapogiannis D. PMID: 29318971; PMCID: PMC6039273.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    75. Dementia prevention, intervention, and care. Lancet. 2017 Dec 16; 390(10113):2673-2734. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, Larson EB, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N. PMID: 28735855.
      View in: PubMed   Mentions: 1945     Fields:    Translation:Humans
    76. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet. 2017 09; 49(9):1373-1384. Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER, Grenier-Boley B, Heilmann-Heimbach S, Chouraki V, Kuzma AB, Sleegers K, Vronskaya M, Ruiz A, Graham RR, Olaso R, Hoffmann P, Grove ML, Vardarajan BN, Hiltunen M, Nöthen MM, White CC, Hamilton-Nelson KL, Epelbaum J, Maier W, Choi SH, Beecham GW, Dulary C, Herms S, Smith AV, Funk CC, Derbois C, Forstner AJ, Ahmad S, Li H, Bacq D, Harold D, Satizabal CL, Valladares O, Squassina A, Thomas R, Brody JA, Qu L, Sánchez-Juan P, Morgan T, Wolters FJ, Zhao Y, Garcia FS, Denning N, Fornage M, Malamon J, Naranjo MCD, Majounie E, Mosley TH, Dombroski B, Wallon D, Lupton MK, Dupuis J, Whitehead P, Fratiglioni L, Medway C, Jian X, Mukherjee S, Keller L, Brown K, Lin H, Cantwell LB, Panza F, McGuinness B, Moreno-Grau S, Burgess JD, Solfrizzi V, Proitsi P, Adams HH, Allen M, Seripa D, Pastor P, Cupples LA, Price ND, Hannequin D, Frank-García A, Levy D, Chakrabarty P, Caffarra P, Giegling I, Beiser AS, Giedraitis V, Hampel H, Garcia ME, Wang X, Lannfelt L, Mecocci P, Eiriksdottir G, Crane PK, Pasquier F, Boccardi V, Henández I, Barber RC, Scherer M, Tarraga L, Adams PM, Leber M, Chen Y, Albert MS, Riedel-Heller S, Emilsson V, Beekly D, Braae A, Schmidt R, Blacker D, Masullo C, Schmidt H, Doody RS, Spalletta G, Longstreth WT, Fairchild TJ, Bossù P, Lopez OL, Frosch MP, Sacchinelli E, Ghetti B, Yang Q, Huebinger RM, Jessen F, Li S, Kamboh MI, Morris J, Sotolongo-Grau O, Katz MJ, Corcoran C, Dunstan M, Braddel A, Thomas C, Meggy A, Marshall R, Gerrish A, Chapman J, Aguilar M, Taylor S, Hill M, Fairén MD, Hodges A, Vellas B, Soininen H, Kloszewska I, Daniilidou M, Uphill J, Patel Y, Hughes JT, Lord J, Turton J, Hartmann AM, Cecchetti R, Fenoglio C, Serpente M, Arcaro M, Caltagirone C, Orfei MD, Ciaramella A, Pichler S, Mayhaus M, Gu W, Lleó A, Fortea J, Blesa R, Barber IS, Brookes K, Cupidi C, Maletta RG, Carrell D, Sorbi S, Moebus S, Urbano M, Pilotto A, Kornhuber J, Bosco P, Todd S, Craig D, Johnston J, Gill M, Lawlor B, Lynch A, Fox NC, Hardy J, ARUK Consortium, Albin RL, Apostolova LG, Arnold SE, Asthana S, Atwood CS, Baldwin CT, Barnes LL, Barral S, Beach TG, Becker JT, Bigio EH, Bird TD, Boeve BF, Bowen JD, Boxer A, Burke JR, Burns JM, Buxbaum JD, Cairns NJ, Cao C, Carlson CS, Carlsson CM, Carney RM, Carrasquillo MM, Carroll SL, Diaz CC, Chui HC, Clark DG, Cribbs DH, Crocco EA, DeCarli C, Dick M, Duara R, Evans DA, Faber KM, Fallon KB, Fardo DW, Farlow MR, Ferris S, Foroud TM, Galasko DR, Gearing M, Geschwind DH, Gilbert JR, Graff-Radford NR, Green RC, Growdon JH, Hamilton RL, Harrell LE, Honig LS, Huentelman MJ, Hulette CM, Hyman BT, Jarvik GP, Abner E, Jin LW, Jun G, Karydas A, Kaye JA, Kim R, Kowall NW, Kramer JH, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lunetta KL, Lyketsos CG, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Morris JC, Murrell JR, Myers AJ, O'Bryant S, Olichney JM, Pankratz VS, Parisi JE, Paulson HL, Perry W, Peskind E, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reisberg B, Reitz C, Ringman JM, Roberson ED, Rogaeva E, et al. PMID: 28714976; PMCID: PMC5669039.
      View in: PubMed   Mentions: 459     Fields:    Translation:HumansCells
    77. Lessons from the Multidomain Alzheimer Preventive Trial. Lancet Neurol. 2017 08; 16(8):585-586. Yassine HN, Schneider LS. PMID: 28721922; PMCID: PMC5812698.
      View in: PubMed   Mentions: 6     Fields:    
    78. Characterizing Highly Benefited Patients in Randomized Clinical Trials. Int J Biostat. 2017 05 20; 13(1). Charu V, Rosenberg PB, Schneider LS, Drye LT, Rein L, Shade D, Lyketsos CG, Frangakis CE. PMID: 28541924; PMCID: PMC6428065.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    79. Preventing Dementia: Many Issues and Not Enough Time. JAMA Neurol. 2017 05 01; 74(5):508-510. DeKosky ST, Schneider LS. PMID: 28319236.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    80. Challenging Assumptions About African American Participation in Alzheimer Disease Trials. Am J Geriatr Psychiatry. 2017 Oct; 25(10):1150-1159. Kennedy RE, Cutter GR, Wang G, Schneider LS. PMID: 28554539; PMCID: PMC5842064.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    81. Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review. JAMA Neurol. 2017 Mar 01; 74(3):339-347. Yassine HN, Braskie MN, Mack WJ, Castor KJ, Fonteh AN, Schneider LS, Harrington MG, Chui HC. PMID: 28114437; PMCID: PMC5812012.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    82. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. Alzheimers Res Ther. 2017 Feb 17; 9(1):10. Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ. PMID: 28212683; PMCID: PMC5316146.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    83. Dementia research priorities-1 - Author's reply. Lancet Neurol. 2017 03; 16(3):181. Schneider LS. PMID: 28229886.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    84. Dementia research priorities-2 - Author's reply. Lancet Neurol. 2017 03; 16(3):182. Schneider LS. PMID: 28229887.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    85. Guideline Watch (October 2014): Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Focus (Am Psychiatr Publ). 2017 Jan; 15(1):110-128. Rabins PV, Rovner BW, Rummans T, Schneider LS, Tariot PN. PMID: 31997970; PMCID: PMC6519627.
      View in: PubMed   Mentions: 26  
    86. Alzheimer's disease and other dementias: update on research. Lancet Neurol. 2017 01; 16(1):4-5. Schneider L. PMID: 27979354.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    87. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016 12 10; 388(10062):2873-2884. Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR, Wischik CM. PMID: 27863809; PMCID: PMC5164296.
      View in: PubMed   Mentions: 160     Fields:    Translation:HumansAnimalsCTClinical Trials
    88. WHO's dementia research priorities: a prescription for failure? Lancet Neurol. 2016 11; 15(12):1202-1203. Schneider LS. PMID: 27751538.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    89. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement. 2017 01; 13(1):8-19. Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C, DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network. PMID: 27583651; PMCID: PMC5218895.
      View in: PubMed   Mentions: 149     Fields:    Translation:Humans
    90. Reduce vascular risk to prevent dementia? Lancet. 2016 Aug 20; 388(10046):738-40. Schneider LS. PMID: 27475274.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    91. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther. 2016 06 30; 8:25. Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS. PMID: 27358067; PMCID: PMC4928349.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    92. R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. Br J Clin Pharmacol. 2016 09; 82(3):784-92. Ho T, Pollock BG, Mulsant BH, Schantz O, Devanand DP, Mintzer JE, Porsteinsson AP, Schneider LS, Weintraub D, Yesavage J, Drye LT, Munro CA, Shade DM, Lyketsos C, Bies R. PMID: 27145364; PMCID: PMC6445501.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    93. Mortality risk in current and new antipsychotic Alzheimer's disease users: Large scale Japanese study. Alzheimers Dement. 2016 07; 12(7):823-30. Arai H, Nakamura Y, Taguchi M, Kobayashi H, Yamauchi K, Schneider LS, J-CATIA Study Group. PMID: 27106669.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    94. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord. 2016 07; 28:41-48. Bang J, Lobach IV, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Gold M, Morimoto BH, Boxer AL, AL-108-231 Investigators. PMID: 27172829; PMCID: PMC4914418.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    95. Principal components analysis of agitation outcomes in Alzheimer's disease. J Psychiatr Res. 2016 08; 79:4-7. Yesavage JA, Taylor JL, Friedman L, Rosenberg PB, Lazzeroni LC, Leoutsakos JS, Kinoshita LM, Perlow MJ, Munro CA, Devanand DP, Drye LT, Mintzer JE, Pollock BG, Porsteinsson AP, Schneider LS, Shade DM, Weintraub D, Lyketsos CG, Noda A, CitAD Research Group. PMID: 27115509; PMCID: PMC4891245.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    96. Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. Am J Psychiatry. 2016 May 01; 173(5):473-80. Leonpacher AK, Peters ME, Drye LT, Makino KM, Newell JA, Devanand DP, Frangakis C, Munro CA, Mintzer JE, Pollock BG, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Porsteinsson AP, CitAD Research Group. PMID: 27032628.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    97. Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol. 2016 Apr; 15(5):455-532. Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, Iqbal K, Jessen F, Johansson G, Jönsson L, Kivipelto M, Knapp M, Mangialasche F, Melis R, Nordberg A, Rikkert MO, Qiu C, Sakmar TP, Scheltens P, Schneider LS, Sperling R, Tjernberg LO, Waldemar G, Wimo A, Zetterberg H. PMID: 26987701.
      View in: PubMed   Mentions: 566     Fields:    Translation:Humans
    98. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar; 12(3):292-323. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR, Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Ass. PMID: 27012484; PMCID: PMC6417794.
      View in: PubMed   Mentions: 685     Fields:    Translation:HumansAnimals
    99. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. Am J Psychiatry. 2016 May 01; 173(5):465-72. Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano CM, Mintzer J, Mulsant BH, Munro CA, Newell JA, Pawluczyk S, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rein L, Rosenberg PB, Shade D, Weintraub D, Yesavage J, Lyketsos CG, CitAD Research Group. PMID: 26771737; PMCID: PMC6419726.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    100. Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials. J Alzheimers Dis. 2016; 50(4):1205-15. Kennedy RE, Cutter GR, Wang G, Schneider LS. PMID: 26836180.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    101. Accelerating stem cell trials for Alzheimer's disease. Lancet Neurol. 2016 02; 15(2):219-230. Hunsberger JG, Rao M, Kurtzberg J, Bulte JWM, Atala A, LaFerla FM, Greely HT, Sawa A, Gandy S, Schneider LS, Doraiswamy PM. PMID: 26704439.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    102. Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. J Psychiatr Res. 2016 Mar; 74:17-21. Newell J, Yesavage JA, Taylor JL, Kraemer HC, Munro CA, Friedman L, Rosenberg PB, Madore M, Chao SZ, Devanand DP, Drye LT, Mintzer JE, Pollock BG, Porsteinsson AP, Schneider LS, Shade DM, Weintraub D, Lyketsos CG, Noda A, CitAD Research Group. PMID: 26736036; PMCID: PMC4744510.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    103. A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. J Pharmacokinet Pharmacodyn. 2016 Feb; 43(1):99-109. Akil A, Bies RR, Pollock BG, Avramopoulos D, Devanand DP, Mintzer JE, Porsteinsson AP, Schneider LS, Weintraub D, Yesavage J, Shade DM, Lyketsos CG. PMID: 26611790; PMCID: PMC4720707.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    104. Estimating Mortality Associated With Antipsychotics and Other Psychotropics--Reply. JAMA Psychiatry. 2015 Oct; 72(10):1058. Maust DT, Schneider LS, Kales HC. PMID: 26287522; PMCID: PMC4845912.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    105. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr. 2015 Dec; 27(12):2059-67. Rosenberg PB, Drye LT, Porsteinsson AP, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Weintraub D, Newell J, Yesavage J, Lyketsos CG, CitAD Research Group. PMID: 26305876; PMCID: PMC4669064.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    106. Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences. J Geriatr Psychiatry Neurol. 2016 Mar; 29(2):59-64. Peters ME, Vaidya V, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Avramopoulos D, CitAD Research Group. PMID: 26303700; PMCID: PMC5166612.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    107. Introducing Alzheimer's & Dementia: Translational Research & Clinical Interventions, an open access journal of the Alzheimer's Association. Alzheimers Dement (N Y). 2015 Jun; 1(1):91-93. Schneider LS. PMID: 29854929; PMCID: PMC5974974.
      View in: PubMed   Mentions:
    108. Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change? Alzheimers Dement (N Y). 2015 Jun; 1(1):46-52. Kennedy RE, Cutter GR, Wang G, Schneider LS. PMID: 27695707; PMCID: PMC5040516.
      View in: PubMed   Mentions: 13  
    109. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. Am J Geriatr Psychiatry. 2015 Nov; 23(11):1127-33. Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Yesavage J, Lyketsos CG, CitAD Research Group. PMID: 26238225; PMCID: PMC4653092.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    110. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015 May; 72(5):438-45. Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC. PMID: 25786075; PMCID: PMC4439579.
      View in: PubMed   Mentions: 188     Fields:    Translation:Humans
    111. Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment. Alzheimers Dement (N Y). 2015 Jun; 1(1):63-71. Wang G, Kennedy RE, Cutter GR, Schneider LS. PMID: 29854926; PMCID: PMC5975045.
      View in: PubMed   Mentions: 1  
    112. Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. Alzheimers Dement (Amst). 2015 Mar; 1(1):103-11. Goldberg TE, Harvey PD, Wesnes KA, Snyder PJ, Schneider LS. PMID: 27239497; PMCID: PMC4876902.
      View in: PubMed   Mentions: 124  
    113. Treatment changes among older patients with dementia treated with antipsychotics. Int J Geriatr Psychiatry. 2015 Dec; 30(12):1238-49. Kim HM, Chiang C, Weintraub D, Schneider LS, Kales H. PMID: 25759986; PMCID: PMC6201312.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    114. Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology. 2015 Mar 17; 84(11):1121-7. Schneider LS, Kennedy RE, Wang G, Cutter GR. PMID: 25681452; PMCID: PMC4371405.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    115. Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol. 2015 Feb; 72(2):209-16. Wang LS, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JD, Cannon-Albright L, Baldwin CT, Zetterberg H, Blennow K, Kukull WA, Faber KM, Schupf N, Norton MC, Tschanz JT, Munger RG, Corcoran CD, Rogaeva E, Alzheimer's Disease Genetics Consortium, Lin CF, Dombroski BA, Cantwell LB, Partch A, Valladares O, Hakonarson H, St George-Hyslop P, Green RC, Goate AM, Foroud TM, Carney RM, Larson EB, Behrens TW, Kauwe JS, Haines JL, Farrer LA, Pericak-Vance MA, Mayeux R, Schellenberg GD, National Institute on Aging-Late-Onset Alzheimer’s Disease (NIA-LOAD) Family Study, Albert MS, Albin RL, Apostolova LG, Arnold SE, Barber R, Barmada M, Barnes LL, Beach TG, Becker JT, Beecham GW, Beekly D, Bennett DA, Bigio EH, Bird TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Burke JR, Buxbaum JD, Cairns NJ, Cao C, Carlson CS, Carroll SL, Chui HC, Clark DG, Cribbs DH, Crocco EA, DeCarli C, DeKosky ST, Demirci FY, Dick M, Dickson DW, Duara R, Ertekin-Taner N, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Glass JD, Graff-Radford NR, Growdon JH, Hamilton RL, Hamilton-Nelson KL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jarvik GP, Jicha GA, Jin LW, Jun G, Jun G, Kamboh MI, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lopez OL, Lunetta KL, Lyketsos CG, Mack WJ, Marson DC, Martin ER, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam WM, Miller BL, Miller CA, Miller JW, Montine TJ, Morris JC, Murrell JR, Olichney JM, Parisi JE, Perry W, Peskind E, Petersen RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reiman EM, Reisberg B, Reitz C, Ringman JM, Roberson ED, Rosen HJ, Rosenberg RN, Sano M, Saykin AJ, Schneider JA, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Tsuang DW, Van Deerlin VM, Van Eldik LJ, Vardarajan BN, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Wishnek S, Woltjer RL, Wright CB, Younkin SG, Yu CE, Yu L. PMID: 25531812; PMCID: PMC4324097.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    116. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother. 2015 Jan; 15(1):83-105. Hampel H, Schneider LS, Giacobini E, Kivipelto M, Sindi S, Dubois B, Broich K, Nisticò R, Aisen PS, Lista S. PMID: 25537424.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimals
    117. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. JAMA Neurol. 2014 Nov; 71(11):1394-404. Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, Beecham GW, Rajbhandary RA, Hamilton-Nelson KL, Wang LS, Kauwe JS, Huentelman MJ, Myers AJ, Bird TD, Boeve BF, Baldwin CT, Jarvik GP, Crane PK, Rogaeva E, Barmada MM, Demirci FY, Cruchaga C, Kramer PL, Ertekin-Taner N, Hardy J, Graff-Radford NR, Green RC, Larson EB, St George-Hyslop PH, Buxbaum JD, Evans DA, Schneider JA, Lunetta KL, Kamboh MI, Saykin AJ, Reiman EM, De Jager PL, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Martin ER, Haines JL, Mayeux RP, Farrer LA, Schellenberg GD, Pericak-Vance MA, Alzheimer Disease Genetics Consortium, Albert MS, Albin RL, Apostolova LG, Arnold SE, Barber R, Barnes LL, Beach TG, Becker JT, Beekly D, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carney RM, Carrasquillo MM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cribbs DH, Crocco EA, DeCarli C, DeKosky ST, Dick M, Dickson DW, Duara R, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lin CF, Lopez OL, Lyketsos CG, Mack WJ, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Murrell JR, Olichney JM, Pankratz VS, Parisi JE, Paulson HL, Peskind E, Petersen RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosen HJ, Rosenberg RN, Sano M, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Valladares O, Van Deerlin VM, Van Eldik LJ, Vardarajan BN, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Wishnek S, Woltjer RL, Wright CB, Younkin SG, Yu CE, Yu L. PMID: 25199842; PMCID: PMC4314944.
      View in: PubMed   Mentions: 98     Fields:    Translation:Humans
    118. Idalopirdine for Alzheimer's disease: written in the stars. Lancet Neurol. 2014 Nov; 13(11):1063-1065. Schneider LS. PMID: 25297011.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    119. 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. Alzheimers Dement. 2014 Oct; 10(5 Suppl):S430-52. Alzheimer's Association National Plan Milestone Workgroup, Fargo KN, Aisen P, Albert M, Au R, Corrada MM, DeKosky S, Drachman D, Fillit H, Gitlin L, Haas M, Herrup K, Kawas C, Khachaturian AS, Khachaturian ZS, Klunk W, Knopman D, Kukull WA, Lamb B, Logsdon RG, Maruff P, Mesulam M, Mobley W, Mohs R, Morgan D, Nixon RA, Paul S, Petersen R, Plassman B, Potter W, Reiman E, Reisberg B, Sano M, Schindler R, Schneider LS, Snyder PJ, Sperling RA, Yaffe K, Bain LJ, Thies WH, Carrillo MC. PMID: 25341459.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    120. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 2014 Jul 22; 83(4):364-73. Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, Köpke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R. PMID: 24944261; PMCID: PMC4115600.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    121. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. PLoS One. 2014; 9(6):e98426. Drye LT, Spragg D, Devanand DP, Frangakis C, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, CitAD Research Group. PMID: 24914549; PMCID: PMC4051660.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    122. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85. Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH, AL-108-231 Investigators. PMID: 24873720; PMCID: PMC4129545.
      View in: PubMed   Mentions: 124     Fields:    Translation:HumansCTClinical Trials
    123. Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. J Am Geriatr Soc. 2014 May; 62(5):985-8. Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Galasko D, Schneider LS, Aisen PS. PMID: 24828933; PMCID: PMC4023903.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    124. Adverse events and dropouts in Alzheimer's disease studies: what can we learn? Alzheimers Dement. 2015 Jan; 11(1):24-31. Henley DB, Sundell KL, Sethuraman G, Schneider LS. PMID: 24613705.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    125. Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease. Alzheimers Dement. 2014 Mar; 10(2):247-50. Schneider LS. PMID: 24698029; PMCID: PMC3979530.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    126. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014 Feb 19; 311(7):682-91. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, CitAD Research Group. PMID: 24549548; PMCID: PMC4086818.
      View in: PubMed   Mentions: 168     Fields:    Translation:Humans
    127. Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. Am J Geriatr Psychiatry. 2014 Jan; 22(1):14-24. Flynn Longmire CV, Drye LT, Frangakis CE, Martin BK, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG, DIADS-2 Research Group. PMID: 24314887; PMCID: PMC3910508.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    128. A new roadmap for drug development for Alzheimer's disease. Nat Rev Drug Discov. 2014 Feb; 13(2):156. Becker RE, Greig NH, Giacobini E, Schneider LS, Ferrucci L. PMID: 24362362; PMCID: PMC4668586.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    129. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44. Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P, EU/US/CTAD Task Force Members. PMID: 23809364.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    130. Moderators of outcome in late-life depression: a patient-level meta-analysis. Am J Psychiatry. 2013 Jun; 170(6):651-9. Nelson JC, Delucchi KL, Schneider LS. PMID: 23598969.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    131. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease. Alzheimers Dement. 2014 May; 10(3):349-59. Kennedy RE, Cutter GR, Schneider LS. PMID: 23712001; PMCID: PMC3900604.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    132. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement. 2013 Sep; 9(5):602-8. Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, Evans J, Lee M, Porsteinsson A, Lanctôt KL, Rosenberg PB, Sultzer DL, Francis PT, Brodaty H, Padala PP, Onyike CU, Ortiz LA, Ancoli-Israel S, Bliwise DL, Martin JL, Vitiello MV, Yaffe K, Zee PC, Herrmann N, Sweet RA, Ballard C, Khin NA, Alfaro C, Murray PS, Schultz S, Lyketsos CG, Neuropsychiatric Syndromes Professional Interest Area of ISTAART. PMID: 23562430; PMCID: PMC3766403.
      View in: PubMed   Mentions: 140     Fields:    Translation:Humans
    133. Alzheimer disease pharmacologic treatment and treatment research. Continuum (Minneap Minn). 2013 Apr; 19(2 Dementia):339-57. Schneider LS. PMID: 23558481; PMCID: PMC10564039.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    134. Quantifying an amyloid β model for Alzheimer's disease. Lancet Neurol. 2013 Apr; 12(4):327-8. Schneider LS. PMID: 23477990.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    135. Antidepressant Treatment of Very Old Patients. Am J Geriatr Psychiatry. 1993 Winter; 1(1):21-29. Salzman C, Schneider L, Lebowitz B. PMID: 28530942.
      View in: PubMed   Mentions: 6     Fields:    
    136. Early intervention with an estrogen receptor β-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease. J Alzheimers Dis. 2013; 37(2):403-19. Zhao L, Mao Z, Chen S, Schneider LS, Brinton RD. PMID: 23948892; PMCID: PMC4197935.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimals
    137. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry. 2012 Dec; 20(12):1036-44. Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG, Depression in Alzheimer’s Disease Study–2 Research Group. PMID: 23032478; PMCID: PMC3508666.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    138. Biomarker positive and negative subjects in the ADNI cohort: clinical characterization. Curr Alzheimer Res. 2012 12; 9(10):1135-41. Kennedy RE, Schneider LS, Cutter GR, Alzheimer's Disease Neuroimaging Initiative. PMID: 22963265.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    139. Ginkgo and AD: key negatives and lessons from GuidAge. Lancet Neurol. 2012 Oct; 11(10):836-7. Schneider LS. PMID: 22959218.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    140. Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology. 2012 Jul 17; 79(3):221-8. Allen M, Zou F, Chai HS, Younkin CS, Crook J, Pankratz VS, Carrasquillo MM, Rowley CN, Nair AA, Middha S, Maharjan S, Nguyen T, Ma L, Malphrus KG, Palusak R, Lincoln S, Bisceglio G, Georgescu C, Schultz D, Rakhshan F, Kolbert CP, Jen J, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N, Alzheimer's Disease Genetics Consortium (ADGC), Apostolova LG, Arnold SE, Baldwin CT, Barber R, Barmada MM, Beach T, Beecham GW, Beekly D, Bennett DA, Bigio EH, Bird TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Burke JR, Buros J, Buxbaum JD, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Crane PK, Cruchaga C, Cummings JL, De Jager PL, DeCarli C, DeKosky ST, Demirci FY, Diaz-Arrastia R, Dick M, Dombroski BA, Duara R, Ellis WD, Evans D, Faber KM, Fallon KB, Farlow MR, Ferris S, Foroud TM, Frosch M, Galasko DR, Gallins PJ, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Goate AM, Green RC, Growdon JH, Hakonarson H, Hamilton RL, Hardy J, Harrell LE, Head E, Honig LS, Huentelman MJ, Hulette CM, Hyman BT, Jarvik GP, Jicha GA, Jin LW, Jun G, Kamboh MI, Karlawish J, Karydas A, Kauwe JS, Kaye JA, Kennedy N, Kim R, Koo EH, Kowall NW, Kramer P, Kukull WA, Lah JJ, Larson EB, Levey AI, Lieberman AP, Lopez OL, Lunetta KL, Mack WJ, Marson DC, Martin ER, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Montine TJ, Morris JC, Myers AJ, Naj AC, Nowotny P, Parisi JE, Perl DP, Peskind E, Poon WW, Potter H, Quinn JF, Raj A, Rajbhandary RA, Raskind M, Reiman EM, Reisberg B, Reitz C, Ringman JM, Roberson ED, Rogaeva E, Rosenberg RN, Sano M, Saykin AJ, Schneider JA, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, St George-Hyslop P, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Tsuang DW, Van Deerlin VM, Vardarajan BN, Vinters HV, Vonsattel JP, Wang LS, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL. PMID: 22722634; PMCID: PMC3398432.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    141. Recruitment methods for United States Alzheimer disease prevention trials. J Nutr Health Aging. 2012 Apr; 16(4):331-5. Schneider LS. PMID: 22499452.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    142. Discontinuing donepezil or starting memantine for Alzheimer's disease. N Engl J Med. 2012 Mar 08; 366(10):957-9. Schneider LS. PMID: 22397659.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    143. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a006395. Aisen PS, Cummings J, Schneider LS. PMID: 22393531; PMCID: PMC3282492.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimals
    144. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90. Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN, Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I, Andreassen OA, Schork NJ, Dale AM, Alzheimer's Disease Neuroimaging Initiative, Pediatric Imaging, Neurocognition, and Genetics Study, Weiner M, Aisen P, Petersen R, Jack CR, Jagust W, Trojanowki JQ, Toga AW, Beckett L, Green RC, Saykin AJ, Morris J, Liu E, Montine T, Gamst A, Thomas RG, Donohue M, Walter S, Gessert D, Sather T, Harvey D, Kornak J, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen K, Mathis C, Cairns NJ, Taylor-Reinwald L, Trojanowki JQ, Shaw L, Lee VM, Korecka M, Crawford K, Neu S, Foroud TM, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder PJ, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider LS, Pawluczyk S, Spann BM, Brewer J, Vanderswag H, Heidebrink JL, Lord JL, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Ances B, Carroll M, Leon S, Mintun MA, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah RC, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon MJ, Glodzik L, De Santi S, Doraiswamy PM, Petrella JR, Coleman RE, Arnold SE, Karlawish JH, Wolk D, Smith CD, Jicha G, Hardy P, Lopez OL, Oakley M, Simpson DM, Porsteinsson AP, Goldstein BS, Martin K, Makino KM, Ismail MS, Brand C, Mulnard RA, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Swerdlow RH, Apostolova L, Lu PH, Bartzokis G, Silverman DH, Graff-Radford NR, Parfitt F, Johnson H, Farlow MR, Hake AM, Matthews BR, Herring S, van Dyck CH, Carson RE, MacAvoy MG, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Hsiung R, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam MM, Lipowski K, Wu CK, Johnson N, Sadowsky C, Martinez W, Villena T, Turner RS, Johnson K, Reynolds B, Sperling RA, Johnson KA, Marshall G, Frey M, Yesavage J, Taylor JL, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson AE, Norbash A, Johnson PL, Obisesan TO, Wolday S, Bwayo SK, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, et al. PMID: 22343285; PMCID: PMC3309762.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimals
    145. Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement. 2012; 8(2):121-30. Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, Pollock BG, Lyketsos CG, CitAD Research Group. PMID: 22301195; PMCID: PMC3333484.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    146. Sertraline for the treatment of depression in Alzheimer disease: genetic influences. J Geriatr Psychiatry Neurol. 2011 Dec; 24(4):222-8. Peters ME, Vaidya V, Drye LT, Rosenberg PB, Martin BK, Porsteinsson AP, Frangakis CE, Mintzer J, Weintraub D, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, Avramopoulos D, Dimitri A, DIADS-2 Research Group. PMID: 22228829; PMCID: PMC3535452.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    147. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012 Jan; 169(1):71-9. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC. PMID: 22193526; PMCID: PMC4269551.
      View in: PubMed   Mentions: 95     Fields:    Translation:Humans
    148. Estrogen receptor β-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause. Menopause. 2011 Oct; 18(10):1131-42. Zhao L, Mao Z, Schneider LS, Brinton RD. PMID: 21738079; PMCID: PMC7577540.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimals
    149. Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease. J Clin Psychiatry. 2012 Jan; 73(1):121-8. Mohamed S, Rosenheck R, Lyketsos CG, Kaczynski R, Sultzer DL, Schneider LS. PMID: 21939611; PMCID: PMC4040971.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    150. Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress. Free Radic Biol Med. 2011 Dec 01; 51(11):2007-17. Schneider L, Giordano S, Zelickson BR, S Johnson M, A Benavides G, Ouyang X, Fineberg N, Darley-Usmar VM, Zhang J. PMID: 21945098; PMCID: PMC3208787.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCells
    151. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR, Thal L, Aisen PS, Alzheimer's Disease Cooperative Study Group. PMID: 21810649; PMCID: PMC7003728.
      View in: PubMed   Mentions: 89     Fields:    Translation:Humans
    152. Reduction of mutant huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons. Mol Neurodegener. 2011 Jun 01; 6:37. Liang Q, Ouyang X, Schneider L, Zhang J. PMID: 21631942; PMCID: PMC3164227.
      View in: PubMed   Mentions: 26     Fields:    
    153. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)? Int J Geriatr Psychiatry. 2011 Jun; 26(6):573-83. Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG, DIADS-2 Research Group. PMID: 20672243; PMCID: PMC3414254.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    154. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry. 2011 Aug; 168(8):831-9. Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS. PMID: 21572163; PMCID: PMC3310182.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    155. Caregiver burden, health utilities, and institutional service use in Alzheimer's disease. Int J Geriatr Psychiatry. 2012 Apr; 27(4):382-93. Miller EA, Rosenheck RA, Schneider LS. PMID: 21560160; PMCID: PMC3204397.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    156. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011 Aug; 68(8):991-8. Schneider LS, Dagerman KS, Higgins JP, McShane R. PMID: 21482915.
      View in: PubMed   Mentions: 90     Fields:    Translation:Humans
    157. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011 May; 43(5):436-41. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD. PMID: 21460841; PMCID: PMC3090745.
      View in: PubMed   Mentions: 1027     Fields:    Translation:Humans
    158. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen PS. PMID: 20921876; PMCID: PMC3526369.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    159. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry. 2011 Feb; 68(2):190-7. Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio RV, Ignacio R, Ganoczy D, Cunningham F, Schneider LS, Blow FC. PMID: 21300946.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    160. Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron. 2011 Jan 27; 69(2):203-13. Golde TE, Schneider LS, Koo EH. PMID: 21262461; PMCID: PMC3058906.
      View in: PubMed   Mentions: 188     Fields:    Translation:Humans
    161. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J Clin Pharmacol. 2011 Nov; 51(11):1587-91. Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, Li CH, Coley K, Kirshner MM, Marder SR. PMID: 21209243.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    162. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol. 2011 Jan; 68(1):58-66. Schneider LS, Insel PS, Weiner MW, Alzheimer's Disease Neuroimaging Initiative. PMID: 21220675; PMCID: PMC3259850.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    163. Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. J Clin Psychopharmacol. 2010 Dec; 30(6):683-7. Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR. PMID: 21105282.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    164. Fixing Alzheimer disease trials by improving process and methods. Curr Alzheimer Res. 2010 Nov; 7(7):564-5. Schneider LS. PMID: 21214512.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    165. Organising the language of Alzheimer's disease in light of biomarkers. Lancet Neurol. 2010 Nov; 9(11):1044-5. Schneider LS. PMID: 20934913.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    166. Caregiver burden, health utilities, and institutional service costs among community-dwelling patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 Oct-Dec; 24(4):380-9. Miller EA, Rosenheck RA, Schneider LS. PMID: 20625266; PMCID: PMC3951163.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    167. Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry. 2010 Oct; 18(10):917-27. Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS. PMID: 20808108; PMCID: PMC3972419.
      View in: PubMed   Mentions: 92     Fields:    Translation:Humans
    168. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 2010 Sep; 6(5):367-77. Schneider LS, Kennedy RE, Cutter GR, Alzheimer’s Disease Neuroimaging Initiative. PMID: 20813339; PMCID: PMC2947209.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    169. Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease. Mol Neurodegener. 2010 Apr 13; 5:14. Schneider L, Zhang J. PMID: 20388210; PMCID: PMC2867960.
      View in: PubMed   Mentions: 27     Fields:    
    170. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010 Apr; 18(4):332-40. Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, DIADS-2 Research Group. PMID: 20220589; PMCID: PMC2849739.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    171. The potential and limits for clinical trials for early Alzheimer's disease and some recommendations. J Nutr Health Aging. 2010 Apr; 14(4):295-8. Schneider LS. PMID: 20305999; PMCID: PMC3923577.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    172. Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation. Int Psychogeriatr. 2011 Feb; 23(1):44-53. Miller EA, Schneider LS, Rosenheck RA. PMID: 20214847; PMCID: PMC3951873.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    173. Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement. 2010 Mar; 6(2):89-97. Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, Buckholtz N, Carrillo M, Ferris S, Greenberg BD, Grundman M, Khachaturian AS, Kuller LH, Lopez OL, Maruff P, Mohs RC, Morrison-Bogorad M, Phelps C, Reiman E, Sabbagh M, Sano M, Schneider LS, Siemers E, Tariot P, Touchon J, Vellas B, Bain LJ. PMID: 20298968; PMCID: PMC4298995.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    174. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010 Feb; 18(2):136-45. Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, DIADS-2 Research Group. PMID: 20087081; PMCID: PMC2842121.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    175. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009 Dec 16; 302(23):2557-64. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH, Tarenflurbil Phase 3 Study Group. PMID: 20009055; PMCID: PMC2902875.
      View in: PubMed   Mentions: 246     Fields:    Translation:Humans
    176. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement. 2009 Sep; 5(5):388-97. Schneider LS, Sano M. PMID: 19751918; PMCID: PMC3321732.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    177. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):260-7. Schneider LS, Raman R, Schmitt FA, Doody RS, Insel P, Clark CM, Morris JC, Reisberg B, Petersen RC, Ferris SH. PMID: 19812469; PMCID: PMC2762354.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    178. Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis. Int J Geriatr Psychiatry. 2009 May; 24(5):539-44. Nelson JC, Delucchi K, Schneider LS. PMID: 19334041.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    179. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry. 2009 May; 166(5):583-90. Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Stroup TS, Sultzer DL, Tariot PN, Vigen C, Schneider LS. PMID: 19369318; PMCID: PMC2891018.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    180. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." A federally funded corporation for the prevention and treatment of cognitive impairment and brain aging. Alzheimers Dement. 2009 Mar; 5(2):172-9. Schneider LS. PMID: 19328454.
      View in: PubMed   Mentions:    Fields:    
    181. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009 Mar; 5(2):85-92. Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ. PMID: 19328434; PMCID: PMC3959165.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    182. The perils of Alzheimer's drug development. Curr Alzheimer Res. 2009 Feb; 6(1):77-8. Schneider LS, Lahiri DK. PMID: 19199878; PMCID: PMC2747724.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    183. Assessing the relationship between health utilities, quality of life, and health services use in Alzheimer's disease. Int J Geriatr Psychiatry. 2009 Jan; 24(1):96-105. Miller EA, Schneider LS, Rosenheck RA. PMID: 19016254.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    184. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain. 2008 Nov 21; 1:17. Qiao L, Hamamichi S, Caldwell KA, Caldwell GA, Yacoubian TA, Wilson S, Xie ZL, Speake LD, Parks R, Crabtree D, Liang Q, Crimmins S, Schneider L, Uchiyama Y, Iwatsubo T, Zhou Y, Peng L, Lu Y, Standaert DG, Walls KC, Shacka JJ, Roth KA, Zhang J. PMID: 19021916; PMCID: PMC2600785.
      View in: PubMed   Mentions: 133     Fields:    Translation:HumansAnimalsCells
    185. Ginkgo biloba extract and preventing Alzheimer disease. JAMA. 2008 Nov 19; 300(19):2306-8. Schneider LS. PMID: 19017919.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    186. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008 Oct 15; 300(15):1774-83. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ, Alzheimer Disease Cooperative Study. PMID: 18854539; PMCID: PMC2684821.
      View in: PubMed   Mentions: 187     Fields:    Translation:Humans
    187. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008 Jul; 16(7):558-67. Nelson JC, Delucchi K, Schneider LS. PMID: 18591576.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    188. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008 Jul; 165(7):844-54. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS, CATIE-AD Study Group. PMID: 18519523; PMCID: PMC2714365.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    189. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. Am J Geriatr Psychiatry. 2008 Jun; 16(6):469-77. Teng E, Ringman JM, Ross LK, Mulnard RA, Dick MB, Bartzokis G, Davies HD, Galasko D, Hewett L, Mungas D, Reed BR, Schneider LS, Segal-Gidan F, Yaffe K, Cummings JL, Alzheimer's Disease Research Centers of California-Depression in Alzheimer's Disease Investigators. PMID: 18515691; PMCID: PMC2989660.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    190. Sociodemographic and clinical correlates of utility scores in Alzheimer's disease. Value Health. 2008 Dec; 11(7):1120-30. Miller EA, Schneider LS, Zbrozek A, Rosenheck RA. PMID: 18489496.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    191. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement. 2008 May; 4(3):156-63. Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ. PMID: 18631960; PMCID: PMC2544623.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    192. Does donepezil improve executive function in patients with CADASIL? Lancet Neurol. 2008 Apr; 7(4):287-9. Schneider LS. PMID: 18296122.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    193. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008 Feb; 48(2):157-65. Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M, Kirshner MA, Schneider LS, Bies RR. PMID: 18199892.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    194. Prevention therapeutics of dementia. Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S122-30. Schneider LS. PMID: 18631988.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    195. Psychometric comparison of computerized and standard administration of the neurocognitive assessment instruments selected by the CATIE and MATRICS consortia among patients with schizophrenia. Schizophr Res. 2008 Nov; 106(1):33-41. O'Halloran JP, Kemp AS, Gooch KN, Harvey PD, Palmer BW, Reist C, Schneider LS. PMID: 18160262.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    196. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry. 2007 Dec; 164(12 Suppl):5-56. APA Work Group on Alzheimer's Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS, Tariot PN, Blass DM, Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, Cook IA, Finnerty MT, Johnson BR, Nininger JE, Schneidman B, Summergrad P, Woods SM, Berger J, Cross CD, Brandt HA, Margolis PM, Shemo JP, Blinder BJ, Duncan DL, Barnovitz MA, Carino AJ, Freyberg ZZ, Gray SH, Tonnu T, Kunkle R, Albert AB, Craig TJ, Regier DA, Fochtmann LJ. PMID: 18340692.
      View in: PubMed   Mentions: 116     Fields:    Translation:Humans
    197. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch Gen Psychiatry. 2007 Nov; 64(11):1259-68. Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS, Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) investigat. PMID: 17984395.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    198. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007 Sep; 6(9):782-92. Kavirajan H, Schneider LS. PMID: 17689146.
      View in: PubMed   Mentions: 111     Fields:    Translation:Humans
    199. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics. Curr Alzheimer Res. 2007 Jul; 4(3):325-35. Ismail MS, Dagerman K, Tariot PN, Abbott S, Kavanagh S, Schneider LS. PMID: 17627490.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    200. Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease? Curr Alzheimer Res. 2007 Jul; 4(3):273-6. Winstein CJ, Bentzen KR, Boyd L, Schneider LS. PMID: 17627484.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    201. Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Wuthering forest plots: distinguishing the forest from the plots. Alzheimers Dement. 2007 Jan; 3(1):18-20. Schneider LS. PMID: 19595911.
      View in: PubMed   Mentions: 2     Fields:    
    202. Design of Depression in Alzheimer's Disease Study-2. Am J Geriatr Psychiatry. 2006 Nov; 14(11):920-30. Martin BK, Frangakis CE, Rosenberg PB, Mintzer JE, Katz IR, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Niederehe G, Lyketsos CG. PMID: 17068314.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    203. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion. 2006 Dec; 6(6):323-30. Valla J, Schneider L, Niedzielko T, Coon KD, Caselli R, Sabbagh MN, Ahern GL, Baxter L, Alexander G, Walker DG, Reiman EM. PMID: 17123871; PMCID: PMC1864936.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCells
    204. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006 Oct 12; 355(15):1525-38. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA, CATIE-AD Study Group. PMID: 17035647.
      View in: PubMed   Mentions: 307     Fields:    Translation:Humans
    205. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S124-38. Schneider LS, Clark CM, Doody R, Ferris SH, Morris JC, Raman R, Reisberg B, Schmitt FA. PMID: 17135806.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansPHPublic Health
    206. Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice. Brain Res. 2006 Oct 20; 1116(1):194-200. Valla J, Schneider L, Reiman EM. PMID: 16942758; PMCID: PMC1851938.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    207. Open-label extension studies and misinformation. Arch Neurol. 2006 Jul; 63(7):1036; author reply 1036-7. Schneider LS. PMID: 16831980.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    208. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006 Mar; 14(3):191-210. Schneider LS, Dagerman K, Insel PS. PMID: 16505124.
      View in: PubMed   Mentions: 261     Fields:    Translation:Humans
    209. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006 Mar; 14(3):280-91. Mintzer J, Greenspan A, Caers I, Van Hove I, Kushner S, Weiner M, Gharabawi G, Schneider LS. PMID: 16505133.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    210. The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London? Int J Geriatr Psychiatry. 2006 Jan; 21(1):9-13. Schneider LS. PMID: 16353164.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    211. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res. 2005 Dec; 2(5):541-51. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. PMID: 16375657.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimals
    212. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005 Oct 19; 294(15):1934-43. Schneider LS, Dagerman KS, Insel P. PMID: 16234500.
      View in: PubMed   Mentions: 454     Fields:    Translation:Humans
    213. Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment. Alzheimer Dis Assoc Disord. 2005 Oct-Dec; 19(4):279-83. Schneider LS. PMID: 16327360.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    214. Mild cognitive impairment. Am J Geriatr Psychiatry. 2005 Aug; 13(8):629-32. Schneider LS. PMID: 16085778.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    215. Meta-analysis of memantine: summary and commentary on the Cochrane Collaboration's systematic review. Alzheimers Dement. 2005 Jul; 1(1):67-71. McShane R, Schneider LS. PMID: 19595819.
      View in: PubMed   Mentions: 3     Fields:    
    216. Symptoms of late-life depression: frequency and change during treatment. Am J Geriatr Psychiatry. 2005 Jun; 13(6):520-6. Nelson JC, Clary CM, Leon AC, Schneider LS. PMID: 15956272.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    217. Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'. Int J Geriatr Psychiatry. 2005 Feb; 20(2):119-27. Rosenberg PB, Onyike CU, Katz IR, Porsteinsson AP, Mintzer JE, Schneider LS, Rabins PV, Meinert CL, Martin BK, Lyketsos CG, Depression of Alzheimer's Disease Study. PMID: 15660424.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    218. Recognizing and responding to atypical antipsychotic side effects. J Am Med Dir Assoc. 2004 Jul-Aug; 5(4 Suppl):H7-10. Jackson-Siegal JM, Schneider LS, Baskys A, Haupt DW. PMID: 15243311.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    219. AD2000: donepezil in Alzheimer's disease. Lancet. 2004 Jun 26; 363(9427):2100-1. Schneider LS. PMID: 15220027.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    220. Estrogen and dementia: insights from the Women's Health Initiative Memory Study. JAMA. 2004 Jun 23; 291(24):3005-7. Schneider LS. PMID: 15213214.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    221. Delay in nursing home placement with donepezil. J Am Geriatr Soc. 2004 Jun; 52(6):1024-6; author reply 1026-7. Schneider LS, Qizilbash N. PMID: 15161477.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    222. Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents. Evid Based Ment Health. 2004 May; 7(2):47. Schneider LS. PMID: 15107343.
      View in: PubMed   Mentions:    Fields:    
    223. Psychosis of Alzheimer's disease: clinical characteristics and history. J Psychiatr Res. 2004 Jan; 38(1):105-11. Schneider LS, Dagerman KS. PMID: 14690773.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    224. Evidence-based practices in geriatric mental health care: an overview of systematic reviews and meta-analyses. Psychiatr Clin North Am. 2003 Dec; 26(4):971-90, x-xi. Bartels SJ, Dums AR, Oxman TE, Schneider LS, Areán PA, Alexopoulos GS, Jeste DV. PMID: 14711131.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    225. Cholinesterase inhibitors for vascular dementia? Lancet Neurol. 2003 Nov; 2(11):658-9. Schneider LS. PMID: 14572732.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    226. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry. 2003 Sep; 64(9):1065-74. Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD. PMID: 14628982.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    227. Choosing treatment for Alzheimer's patients and their caregivers. Geriatrics. 2003 Aug; 58 Suppl 1:3-18, 23; quiz 19-22. Schneider LS, Porsteinsson AP, Peskin ER, Pfeiffer EA. PMID: 12961833.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    228. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. Am J Geriatr Psychiatry. 2003 Jul-Aug; 11(4):414-25. Schneider LS, Katz IR, Park S, Napolitano J, Martinez RA, Azen SP. PMID: 12837670.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    229. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry. 2003 Jul; 160(7):1277-85. Schneider LS, Nelson JC, Clary CM, Newhouse P, Krishnan KR, Shiovitz T, Weihs K, Sertraline Elderly Depression Study Group. PMID: 12832242.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    230. Cholinesterase inhibitors for Alzheimer disease. JAMA. 2003 May 14; 289(18):2359-60; author reply 2360-1. Schneider LS. PMID: 12746354.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    231. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets. 2003 Feb; 4(2):97-112. Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS. PMID: 12558063.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimals
    232. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophr Bull. 2003; 29(1):57-72. Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D, Pfeiffer E, Ryan JM, Sultzer DL, Tariot PN. PMID: 12908661.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    233. Provisional diagnostic criteria for depression of Alzheimer's disease: description and review. Expert Rev Neurother. 2003 01; 3(1):99-106. Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Jeste DV, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, Reynolds CF, Rovner BW, Steffens DC, Unützer J, Lebowitz BD. PMID: 19810852.
      View in: PubMed   Mentions: 8     Fields:    
    234. The increasing power of placebos in trials of antidepressants. JAMA. 2002 Jul 24-31; 288(4):450. Schneider LS, Small GW. PMID: 12132971.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    235. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002 Mar-Apr; 10(2):125-8. Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, Reynolds CF, Rovner BW, Steffens DC, Tariot PN, Lebowitz BD. PMID: 11925273.
      View in: PubMed   Mentions: 89     Fields:    Translation:Humans
    236. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry. 2002 Mar-Apr; 10(2):129-41. Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. PMID: 11925274.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    237. Investigating emergent symptomatology as an outcome measure in a behavioral study of Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2002; 14(3):303-10. Tractenberg RE, Gamst A, Thomas RG, Patterson M, Schneider LS, Thal LJ. PMID: 12154155; PMCID: PMC4371727.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    238. Treatment of Alzheimer's disease with cholinesterase inhibitors. Clin Geriatr Med. 2001 May; 17(2):337-58. Schneider LS. PMID: 11375139.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    239. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry. 2001; 9(4):346-60. Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Rosenheck RA, Small GW, Lebowitz B, Lieberman JA. PMID: 11739062.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    Lon's Networks
    Concepts (519)
    Derived automatically from this person's publications.
    _
    Co-Authors (125)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _